
CORRECTION



Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). *J Am Acad Dermatol.* 2017;77:855-862.

In the above article, there were incorrect data provided in the manuscript body. A corrected version of the paragraph is below; corrected text is underlined.

Following week sixty, 48 of 1274 (3.8%) patients increased ixekizumab dosage to 80 mg every 2 weeks at the investigator's decision. At the visit the investigator decided to adjust the dose, which was usually 2 weeks before dose escalation, 21 (43.8%) patients had an sPGA score of 3 (moderate disease) and the remaining 27 had an sPGA score of ≤ 2 . In addition, at the visit the investigator decided to adjust the dose, 34 (70.8%) patients who increased dosage to ixekizumab every 2 weeks reported PASI 75 or better, 10 (20.8%) reported PASI 90 or better, and 1 (2.1%) reported PASI 100.